Epigenetic inhibitors as a promising new antimalarial intervention strategy? A new study identifies an inhibitor of gene regulation that specifically kills the malaria pathogen. A multinational ...

Plasmodium falciparum has evolved resistance to virtually every antimalarial introduced for widespread use, posing a major challenge to malaria control and elimination. Resistance emerged first ...

This activity was supported by Contract Order No. VA 36C24E18C0067 between the National Academy of Sciences and the Department of Veterans Affairs. Any opinions, findings, conclusions, or ...

The Calibr-Skaggs Institute for Innovative Medicines at Scripps Research and Kainomyx, Inc., today announced a new research collaboration to accelerate the discovery and development of next-generation ...

Scientists from Drexel University’s College of Medicine and Columbia University’s Irving Medical Center have uncovered a crucial structural feature of a key malaria drug target, known as PfATP4, and ...

Researchers have developed a new antimalarial drug candidate designed to address the growing challenge of drug resistance and potentially reduce malaria transmission. The first-in-class clinical ...

This cartoon shows the newly identified mefloquine binding site causing the changes in the ribosome's dynamics which promote read-through of the premature stop codons. The main interactions are shown ...

Researchers led by teams at the University of California, Riverside (UCR), the University of California, Irvine, and the Yale School of Medicine have developed a compound that they found to be ...

The antimalarial drug mefloquine could help treat genetic diseases such as cystic fibrosis, Duchenne muscular dystrophy, as well as some cancers. In these diseases, a mutation in the genetic code ...

Plasmodium falciparum poses a persistent threat to malaria control due to its capacity to acquire and propagate mutations that compromise antimalarial efficacy. Central to this adaptability are ...